Samsung Bioepis Unveils Promising Nonclinical Data for Novel ADC Candidate SBE303
Event summary
- Samsung Bioepis presented nonclinical data for its first novel ADC candidate, SBE303, at the AACR 2026 Annual Meeting on April 20, 2026.
- SBE303 targets Nectin-4, an adhesion protein expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.
- Nonclinical results showed robust anti-tumor activity with a differentiated tolerability profile and no intestinal lung disease findings at doses ≥40 mg/kg.
- SBE303 is currently under Phase I clinical development (NCT07524348).
The big picture
Samsung Bioepis is expanding its portfolio beyond biosimilars with the development of novel ADCs, positioning itself in the competitive oncology market. The promising nonclinical data for SBE303 highlights the company's commitment to innovation and its potential to address unmet needs in cancer treatment. The success of SBE303 could significantly impact Samsung Bioepis' strategic shift towards developing proprietary therapeutics.
What we're watching
- Clinical Development Pace
- How quickly Samsung Bioepis advances SBE303 through Phase I clinical trials and potential regulatory hurdles.
- Combination Therapy Potential
- Whether SBE303's ability to work in combination with existing immuno-oncology therapies will enhance its market positioning.
- Therapeutic Index Validation
- The extent to which the improved therapeutic index of SBE303 translates into clinical efficacy and safety benefits.
Related topics